Nonvenereal Syphilis Treatment Market Size & Share, by Treatment (Antibiotics, Topical Treatment); Diagnosis (Lesions Testing, Dark-Field Microscopy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3569
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Nonvenereal Syphilis Treatment Landscape

    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Novartis International AG
    • Sanofi S.A.
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Otsuka Pharmaceutical Co., Ltd.,
    • Abbott Laboratories
    • Cipla Limited

Browse Key Market Insights with Data Illustration:


In The News

  • Cipla Limited a multinational pharmaceutical company joint hands with Kemwell Biopharma Private Limited, a leading global CDMO, to make cost-effective biotherapeutics.

  • Sandoz, a subsidiary of Novartis, expanded its portfolio in manufacturing antibiotics with the acquisition of the Cephalosporin antibiotics business of GSK.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3569
  • Published Date: Apr 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising cases of bejel as well as the increasing augmentation of infectious diseases are the major growth factors driving the growth of the market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2023-2035.

Challenges in the diagnostic landscape and testing models are estimated to be the growth hindering factors for the market expansion.

The market in the Middle East and Africa region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment, diagnosis, and by region.

The antibiotics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying